You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD7

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

Not yet recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • CD7-CART01
  • (no location specified)
Sep 26, 2023

Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)

Recruiting
  • Hematologic Diseases
  • Neoplasms
  • CD7 CAR-T cells injection
  • Allogeneic hematopoietic stem cell transplantation
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 11, 2023

Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)

Recruiting
  • CD7+ Acute Leukemia
  • CD7+ Lymphoma
  • anti-CD7 CAR-T
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Sep 18, 2022

Hematological Malignancies Trial (Anti-CD7 CAR-T)

Not yet recruiting
  • Hematological Malignancies
  • Anti-CD7 CAR-T
  • (no location specified)
Jul 8, 2022

T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • CD7 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Nov 11, 2022

Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)

Recruiting
  • Hematologic Malignancies
  • RD13-02 cell infusion
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jun 26, 2023

T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • Shanghai, China
    Xianmin General Song
Aug 29, 2022

Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +2 more
  • RD13-02 cell infusion
  • Xuzhou, Jiangsu, China
    Affiliated hospital of Xuzhou medical college
Jun 7, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Tumors, Hematologic Tumors, Hematologic Diseases Trial in Hefei (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +2 more
  • RD13-02 cell infusion
  • Hefei, Anhui, China
    The First Affiliated Hospital of University of Science and Techn
Jun 5, 2023

Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Jun 8, 2023

Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma Trial in Langfang (CD7CAR T cells)

Recruiting
  • Relapsed/Refractory, High Risk Hematologic Malignancies
  • T-ALL/Lymphoma
  • CD7CAR T cells
  • Langfang, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Jun 30, 2022

Leukemia, T Cell Trial in Beijing (CD7 CART)

Recruiting
  • Leukemia, T Cell
  • CD7 CART
  • Beijing, Hebei, China
    He bei Yan da Lu dao pei Hospital
May 24, 2022

T-Cell Acute Lymphocytic Leukemia Trial in Langfang (CD7 CAR-T)

Recruiting
  • T-Cell Acute Lymphocytic Leukemia
  • CD7 CAR-T
  • Langfang, Hebei, China
    Hebei Yanda Hospital
Jun 26, 2023

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

T-cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Beijing (Senl-T7)

Recruiting
  • T-cell Acute Lymphoblastic Leukemia/Lymphoma
  • Senl-T7
  • Beijing, Hebei, China
    Hebei yanda Hospital
Nov 22, 2022

Lymphoma, T-Cell Trial in Yanda (Senl-T7)

Recruiting
  • Lymphoma, T-Cell
  • Senl-T7
  • Yanda, Hebei, China
    Hebei yanda Ludaopei Hospital
May 24, 2022

T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)

Withdrawn
  • T-cell Acute Lymphoblastic Leukemia
  • T-lymphoblastic Lymphoma
  • Target CD7 CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Nov 23, 2022

T-ALL, Lymphoma, T-Cell Trial in Wuhan (SENL101)

Recruiting
  • T-ALL
  • Lymphoma, T-Cell
  • SENL101
  • Wuhan, Hubei, China
    Tongji Hospital
May 29, 2022

Crohn Disease, Ulcerative Colitis, Dermatomyositis Trial in Hangzhou (CD7 CAR T-cells)

Recruiting
  • Crohn Disease
  • +4 more
  • CD7 CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 13, 2022

T Cell Lymphoma, T-cell Leukemia Trial in Beijing (chimeric antigen receptor T cell treatment)

Recruiting
  • T Cell Lymphoma
  • T-cell Leukemia
  • chimeric antigen receptor T cell treatment
  • Beijing, Beijing, China
    Beijing Boren Hospital
Aug 12, 2022

T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence Trial in Beijing (chimeric antigen

Recruiting
  • T-cell Leukemia/Lymphoma
  • +2 more
  • chimeric antigen receptor T cell treatment
  • Beijing, Beijing, China
    Beijing Boren Hospital
Jul 31, 2022

T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)

Recruiting
  • T-lymphoblastic Lymphoma
  • T-ALL
  • CAR-T
  • Shanghai, China
    Shanghai Ruijin Hospital
Nov 14, 2023